MindRank’s oral GLP-1 is the furthest along any AI-native drug programme
MindRank, a Hangzhou drug developer built around AI, says its lead candidate went from programme initiation to Phase III trials in roughly four and a half years on about $23mn of cumulative research spending.
If that holds up, it is the most concrete answer yet to a question the sector has been asking loudly and answering thinly, which is whether AI actually changes the economics of drug development or merely the vocabulary.
The candidate itself is in a fiercely contested class. MDR-001 is an oral small-molecule GLP-1 receptor agonist, putting it in the obesity and diabetes market that has reorganised the pharmaceutical industry over the past five years.
The established GLP-1 drugs are injectables, and a small molecule taken as a pill would be cheaper to manufacture and considerably easier to distribute at scale, which is why every large pharmaceutical company has a programme chasing it.
The company closed...
Copyright of this story solely belongs to thenextweb.com. To see the full text click HERE
